Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure - Study Results

Study Type:	Interventional
Study Design:	Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment
Condition:	Stage 1 or 2 Essential Hypertension
Interventions:	Drug: lisinopril + placebo Drug: carvedilol controlled release/lisinopril

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Lisinopril	Lisinopril monotherapy (10, 20, or 40 mg once daily)
Carvedilol CR + Lisinopril	Carvedilol controlled release (CR) + lisinopril (20 + 10, 20 + 20, or 40 + 20 mg once daily)

Participant Flow: Overall Study

	Lisinopril	Carvedilol CR + Lisinopril
STARTED	216	216
COMPLETED	197	192
NOT COMPLETED	19	24
Adverse Event	5	6
Lost to Follow-up	4	1
Consent withdrawn	6	5
Lack of Efficacy	0	3
Met protocol-defined stopping criteria	4	9

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Lisinopril	Lisinopril monotherapy (10, 20, or 40 mg once daily)
Carvedilol CR + Lisinopril	Carvedilol controlled release (CR) + lisinopril (20 + 10, 20 + 20, or 40 + 20 mg once daily)

Baseline Measures

	Lisinopril	Carvedilol CR + Lisinopril	Total
Number of Participants [units: participants]	216	216	432
Age [units: years] Mean ± Standard Deviation	54.0 ± 11.9	54.1 ± 9.8	54.1 ± 10.9
Gender [units: participants]
Female	95	95	190
Male	121	121	242
Race/Ethnicity, Customized [units: Participants]
African American/African Heritage (AA/AH)	45	29	74
American Indian or Alaska Native	1	2	3
Japanese/East Asian/South East Asian Heritage	16	6	22
Mixed Asian Heritage	1	0	1
White	150	178	328
AA/AH & American Indian or Alaska Native	2	0	2
AA/AH & American Indian or Alaska Native & White	1	0	1
AA/AH & White	0	1	1
Baseline Blood Pressure [units: mm/Hg] Mean ± Standard Deviation
Baseline Sitting Systolic Blood Pressure (SBP)	149.8 ± 10.25	148.8 ± 10.30	149.3 ± 10.27
Baseline Sitting Diastolic Blood Pressure (DBP)	92.2 ± 8.12	92.2 ± 6.84	92.2 ± 7.50

Outcome Measures

Hide All Outcome Measures

1. Primary:

Number of Participants With Mean Sitting Cuff Blood Pressure <140/90 mmHg at the End of 6 Weeks of Treatment [ Week 6 ]

Measure Type	Primary
Measure Title	Number of Participants With Mean Sitting Cuff Blood Pressure <140/90 mmHg at the End of 6 Weeks of Treatment
Measure Description	Sitting cuff blood pressure was calculated as the mean of three measurements taken approximately 2 minutes apart, and before the morning dose.
Time Frame	Week 6
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent to Treat Efficacy (ITTE) Population: all randomized participants with efficacy (vital signs) data after a minimum of 4 weeks of treatment

Reporting Groups

	Description
Lisinopril	Lisinopril monotherapy (10, 20, or 40 mg once daily)
Carvedilol CR + Lisinopril	Carvedilol controlled release (CR) + lisinopril (20 + 10, 20 + 20, or 40 + 20 mg once daily)

Measured Values

	Lisinopril	Carvedilol CR + Lisinopril
Number of Participants Analyzed [units: participants]	203	201
Number of Participants With Mean Sitting Cuff Blood Pressure <140/90 mmHg at the End of 6 Weeks of Treatment [units: Participants]
Responders (mean BP <140/90 mmHg)	139	137
Non-responders (SBP >/=140 mmHg or DBP >/=90 mmHg)	64	64

Statistical Analysis 1 for Number of Participants With Mean Sitting Cuff Blood Pressure <140/90 mmHg at the End of 6 Weeks of Treatment

Groups ^[1]	All groups
Method ^[2]	Regression, Logistic
P Value ^[3]	0.8822
Odds Ratio (OR) ^[4]	0.968
95% Confidence Interval	( 0.63 to 1.49 )

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Other relevant information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.
[4]	Other relevant estimation information:
	No text entered.

2. Secondary:

Mean Change From Baseline in Sitting Systolic Blood Pressure (sSBP) and Sitting Diastolic Blood Pressure (sDBP) at Week 6 [ Baseline and Week 6 ]

Measure Type	Secondary
Measure Title	Mean Change From Baseline in Sitting Systolic Blood Pressure (sSBP) and Sitting Diastolic Blood Pressure (sDBP) at Week 6
Measure Description	Mean change was calculated as Week 6 values minus Baseline values.
Time Frame	Baseline and Week 6
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITTE

Reporting Groups

	Description
Lisinopril	Lisinopril monotherapy (10, 20, or 40 mg once daily)
Carvedilol CR + Lisinopril	Carvedilol controlled release (CR) + lisinopril (20 + 10, 20 + 20, or 40 + 20 mg once daily)

Measured Values

	Lisinopril	Carvedilol CR + Lisinopril
Number of Participants Analyzed [units: participants]	203	201
Mean Change From Baseline in Sitting Systolic Blood Pressure (sSBP) and Sitting Diastolic Blood Pressure (sDBP) at Week 6 [units: mmHg] Mean ± Standard Deviation
sSBP (mmHg)	-17.05 ± 12.27	-16.07 ± 13.49
sDBP (mmHg)	-10.15 ± 7.52	-9.14 ± 9.65

No statistical analysis provided for Mean Change From Baseline in Sitting Systolic Blood Pressure (sSBP) and Sitting Diastolic Blood Pressure (sDBP) at Week 6

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343

No publications provided

Responsible Party:	GSK ( Study Director )
Study ID Numbers:	COR111096
Study First Received:	February 14, 2008
Results First Received:	June 11, 2009
Last Updated:	September 11, 2009
ClinicalTrials.gov Identifier:	NCT00624065 History of Changes
Health Authority:	United States: Food and Drug Administration